The present study retrospectively collected data of 77 pts (54 m, 23 f) with CDGP followed in 9 Italian centres. Despite similar characteristics at diagnosis, the pts underwent different diagnostic and therapeutic protocols. Inclusion criteria: all pts had at diagnosis short stature and idiopathic delayed puberty. At diagnosis age was 13.8±1.0 yrs in males, height (Ht) sds -2.5±0.6. In females age 13.1±0.9 yrs and Ht sds -2.5±0.6. Protocols. 42 pts were tested for GHD and the 32 (25 m, 7 f) with deficient secretion received GH therapy for at least 2yrs. The 11 non GHD pts were given either no treatment (3 m, 3 f) or testo. depot for 3-12 months (5 m). The 35 pts deliberately not tested for GHD received either no treatment (15 m, 13 f) or testo. (7 m). In males FH (° p=0.004) and ΔFH-target Ht sds (°p=0.05) were higher in the GH treated group than the testo treated group. In females there were no significant differences with tendentially better results in the untreated group. In males 70.8% of the GH treated and 70.6% of the untreated group reached a FH above target Ht vs 18.2% of the testo. treated group (p=0.007). In females 1/7 in the GH treated vs 10/16 in the untreated group reached a FH above target Ht (p=0.04). In conclusion the management of pts with CDGP are not uniform among Pediatric Endocrinologists. In males a non significant better result vs untreated patients was obtained in the patients treated with GH after a diagnosis of GHD, while testosterone treated patients reached a significantly worse result. In females GH therapy did not affect the final result.

Final height (FH) in 77 patients af fected by constitutional delay of growth and puberty (CDGP) variously treated

CISTERNINO, MARIANGELA;
2005-01-01

Abstract

The present study retrospectively collected data of 77 pts (54 m, 23 f) with CDGP followed in 9 Italian centres. Despite similar characteristics at diagnosis, the pts underwent different diagnostic and therapeutic protocols. Inclusion criteria: all pts had at diagnosis short stature and idiopathic delayed puberty. At diagnosis age was 13.8±1.0 yrs in males, height (Ht) sds -2.5±0.6. In females age 13.1±0.9 yrs and Ht sds -2.5±0.6. Protocols. 42 pts were tested for GHD and the 32 (25 m, 7 f) with deficient secretion received GH therapy for at least 2yrs. The 11 non GHD pts were given either no treatment (3 m, 3 f) or testo. depot for 3-12 months (5 m). The 35 pts deliberately not tested for GHD received either no treatment (15 m, 13 f) or testo. (7 m). In males FH (° p=0.004) and ΔFH-target Ht sds (°p=0.05) were higher in the GH treated group than the testo treated group. In females there were no significant differences with tendentially better results in the untreated group. In males 70.8% of the GH treated and 70.6% of the untreated group reached a FH above target Ht vs 18.2% of the testo. treated group (p=0.007). In females 1/7 in the GH treated vs 10/16 in the untreated group reached a FH above target Ht (p=0.04). In conclusion the management of pts with CDGP are not uniform among Pediatric Endocrinologists. In males a non significant better result vs untreated patients was obtained in the patients treated with GH after a diagnosis of GHD, while testosterone treated patients reached a significantly worse result. In females GH therapy did not affect the final result.
2005
9783805580076
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/580901
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact